THSNA 2024 - Chicago, IL

PROGRAM MENU

EDUCATIONAL PROGRAM

PRE-SUMMIT WORKSHOPS

Workshop Schedule

SATELLITE SYMPOSIA

Host a Satellite Symposium

Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2024 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.

Wed - Apr 03

Thu - Apr 04

Fri - Apr 05

Sat - Apr 06

View Program Details

FRIDAY, APRIL 5

6:30 - 8:00 PM

EVENT/OTHER

REGISTRATION
Chicago Promenade

7:00 - 8:00 AM

SATELLITE SYMPOSIUM

ADVANCES IN ITTP MANAGEMENT - CONTEMPORARY CLINICAL APPROACHES (SPONSORED BY SANOFI)
Chicago Ballroom VI

Please join our Sanofi Medical Affairs Rare Blood Disorders team for our medical symposium to gain expert insights on prioritizing clinical management of aTTP/iTTP, focusing on early treatment, and achieving durable responses from therapies, ultimately resulting in improved clinical outcomes. The symposium will be presented in two parts and will illustratively describe the iTTP pathophysiology, epidemiology/diagnostic considerations, before discussing the ISTH guidelines on diagnosis and treatment of iTTP and important implications on clinical management of iTTP.

HEMOSTASIS 2. 0: RETHINKING HEMOPHILIA MANAGEMENT AND MONITORING WITH ANTI-TFPIS AND FVIII MIMETICS (IN PARTNERSHIP WITH CME OUTFITTERS, LLC. SUPPORTED BY AN EDUCATIONAL GRANT FROM NOVO NORDISK, INC. )
Chicago Ballroom IX-X

In this CME Outfitters live activity, experts in hemophilia, including a patient who has lived with the disorder for many years, discuss the role of these newer therapies, how they work, and how to implement them in practice to improve quality of care and outcomes. A focused exercise in shared decision making keeps the conversation grounded in counseling and care and includes both clinician and patient perspectives. This activity is certified for 1. 0 hours of ACCME, ANCC, AAPA, and ABIM MOC II credit. In-person attendee CE Link: https://myportal. cmeoutfitters. com/course/start/3280d955-5a0b-44e5-902d-f07cf8efc4a0 Virtual attendee CE Link: https://myportal. cmeoutfitters. com/course/start/4f71180e-766e-4789-8097-059646d3524c

8:15 - 9:45 AM

LABORATORY

EVOLUTION OF THE CLINICAL HEMOSTASIS/THROMBOSIS LABORATORY
Chair/Organizer: Karen Moser, Jing Jin
Chicago Ballroom VII

8:15

EVOLUTION OF HEMOSTASIS/THROMBOSIS LABORATORY PHYSICIAN ROLE--CLINICAL CONSULTANT
Evelyn Cortina.

8:45

EVOLUTION OF HEMOSTASIS/THROMBOSIS LABORATORY PROFESSIONAL ROLE AT THE BENCH
Jing Jin.

9:15

EVOLUTION OF HEMOSTASIS/THROMBOSIS LABORATORY METHODS INCLUDING LABORATORY AUTOMATION (ELISA-->LIA, MANUAL-->AUTOMATED ADAMTS13, ON-DEMAND VS. BATCH TESTING, NEW VON WILLEBRAND ASSAYS)
Rusty Higgins.

8:15 - 9:45 AM

THROMBOSIS / BASIC SCIENCE

FXI & FXII
Chair/Organizer: William Dager, Maria Santaella
Sheraton Ballroom IV-V

8:15

THE ROLE OF FACTOR XII IN ECMO-ASSOCIATED THROMBOINFLAMMATION
Joe Palumbo.

8:45

ROLE OF ANTIPLATELET AND ANTICOAGULANT THERAPY IN VENO-OCCLUSIVE CRISIS (VOC)
Erica Sparkenbaugh.

9:15

STATE OF THE ART ON FXI AND FXII INHIBITOR DATA
Jeff Weitz.

8:15 - 9:45 AM

HEMOSTASIS

NOT YOUR MOM'S JEANS: UPDATES ON GENE THERAPY FOR HEMOPHILIA PATIENTS
Chair/Organizer: Allison Wheeler, Vinai Bhagirath
Sheraton Ballroom I-II

8:15

CONSIDERING GENE THERAPY IN THE CONTEXT OF NEW OPTIONS FOR MANAGEMENT OF HEMOPHILIA
Ben Samelson-Jones.

8:45

LIVER DISEASE IN THE ERA OF GENE THERAPY
Ype P De Jong.

9:15

MANAGING MEDICAL CHALLENGES OF GENE THERAPY
Stacy Croteau.

9:45 - 10:30 AM

POSTERS/EXHIBITS/BREAK

POSTERS/EXHIBITS/BREAK (click to view) (click to close)
Riverwalk AB

A1. ANTICOAGULATION CLINICS

401

ANALYSIS OF PHARMACIST INTERVENTIONS WITHIN A DIRECT ORAL ANTICOAGULATION MANAGEMENT PROTOCOL
Clara J Nickel², Anne E Rose¹. ¹University of Wisconsin Health, Madison, WI, USA. ²University of Wisconsin School of Pharmacy, Madison, WI, USA

A3. VASCULAR WALL BIOLOGY, ENDOTHELIAL PROGENITOR CELLS AND PLATELET ADHESION

402

CHARACTERIZATION OF THE ENDOTHELIAL CELL SUBPOPULATIONS MARKED BY TEK AND CDH5 PROMOTER DRIVEN CRE EXPRESSION IN DIFFERENT MOUSE STRAINS
David Svilar^{1, 2}, Audrey Cleuren^{1, 3}, David Siemieniak¹, David Ginsburg^{1, 2, 4, 5}. ¹Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA. ²Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA. ³Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA. ⁴Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. ⁵Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA

A4. DISORDERS OF PLATELET NUMBER OR FUNCTION

403

ELECTRONIC MEDICAL RECORD INTERVENTIONS IN REDUCING INAPPROPRIATE TESTING FOR HEPARIN INDUCED THROMBOCYTOPENIA: EXPERIENCE IN A LARGE TEACHING HOSPITAL SYSTEM
Mukul Singal^{1, 2}, Soon K. Low^{3, 4}, Peter A. Kouides^{5, 6}, Maura Wychowski⁶, Ronald L. Sham^{5, 6}. ¹Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA. ²Hematology and Oncology Fellowship, Rochester General Hospital, Rochester, NY, USA. ³Internal Medicine Residency Program, Rochester General Hospital, Rochester, NY, USA. ⁴Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. ⁵Mary M. Gooley Hemophilia and Thrombosis Center, Rochester, NY, USA. ⁶Department of Hematology and Oncology, Rochester General Hospital, Rochester, NY, USA

A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS

404

ARTIFICIAL INTELLIGENCE AND VENOUS THROMBOEMBOLISM: TALKING TO THE EXPERTS
Anuranita Gupta¹, Barbara D Lam^{2, 13}, Sabrina Zerbey², William Robertson³, Rachel P Rosovsky⁴, Leslie Lake⁵, Laura Dodge⁶, Alys Adamski⁷, Nimia Reyes⁷, Karon Abe⁷, Ioannis Vlachos⁸, Jeffrey I Zwicker^{9, 10}, Mara Schonberg¹¹, Rushad Patell¹². ¹Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA. ²Division of Hematology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA. ³Weber State University, Ogden, UT. ⁴Division of Hematology a Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA. ⁵National Blood Clot Alliance, Philadelphia, PA. ⁶Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA. ⁷Division of Blood Disorders and Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA. ⁸Department of Pathology, Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, MA. ⁹Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NYC, NY. ¹⁰Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NYC, NY. ¹¹Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, MA. ¹²Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. ¹³Division of Clinical Informatics, Beth Israel Deaconess Medical Center, Boston, MA

A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS

405

T-HLPER CYTOKINE INTERACTIONS WITH BAFF IN THE FACTOR VIII IMMUNE RESPONSE
Tammi L. Briscoe¹, Mostafa A. Shaheen¹, Bhavya S. Doshi^{1, 2}. ¹Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. ²Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

406

SURGICAL AND PROCEDURAL OUTCOMES FOR PATIENTS WITH FACTOR VIII DEFICIENCY TAKING EMICIZUMAB PROPHYLACTICALLY: A REGIONAL APPROACH TO DATA COLLECTION AND ANALYSIS
Janice Kuhn¹, Butler Regina², Mailie-Howell Lisa², Druzgal Colleen³, Sennett Margy³. ¹Virginia Commonwealth University, Richmond, VA, USA. ²Children's Hospital of Philadelphia, Philadelphila, PA, USA. ³University of Virginia, Charlottesville, VA, USA

407

TRENDS OF ACUTE ISCHEMIC STROKE IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: A DECADE STUDY
Ayobami Olafimihan¹, Stanley ozogbo², Praise fawehinmi³, Gbolahan Olatunji⁴, Emmanuel Kokori⁴, Aderinto Nicholas⁵, Ekrem Turk¹, Lina George¹, Shaka Hafeez¹. ¹John H. Stroger Jr Hospital, Chicago, IL, USA. ²Mercy Health- St. Elizabeth Hospital, Youngstown, OH, USA. ³Southern Illinois University Edwardsville, Chicago, IL, USA. ⁴University of Ilorin, Ilorin, Nigeria. ⁵Ladoke Akintola University of Technology, Ogbomosho, Nigeria

408

SUSTAINED EFFICACY AND SAFETY 3 YEARS FOLLOWING INFUSION WITH ETRANACOGENE DEZAPARVOVEC IN ADULTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA B IN THE PHASE 3 HOPE-B CLINICAL TRIAL
Steven W. Pipe¹, Paul van der Valk², Peter Verhamme³, Peter Kampmann⁴, Frank Leebeek⁵, Michiel Coppens⁶, Nigel Key⁷, Nathan Visweshwar⁸, Guy Young⁹, Richard Lemons¹⁰, Robert Klamroth¹¹, Niamh O'Connell¹², Sandra le Quellec¹³, Paul Monahan¹³, Cedric Hermans¹⁴. ¹Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA. ²Van Creveldkliniek, University Medical Center Utrecht, Utrecht, Netherlands. ³Center for Molecular and Vascular Biology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium. ⁴Rigshospitalet, Copenhagen, Denmark. ⁵Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands. ⁶Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands. ⁷University of North Carolina, Chapel Hill, NC, USA. ⁸University of South Florida, Tampa, FL, USA. ⁹University of Southern California Keck School of Medicine, Childrena, Los Angeles, CA, USA. ¹⁰University of Utah, Salt Lake City, UT, USA. ¹¹Vivantes Klinikum im Friedrichshain, Berlin, Germany. ¹²National Coagulation Centre, St. Jamesa, Dublin, Ireland. ¹³CSL Behring, King of Prussia, PA, USA. ¹⁴Division of Haematology, Cliniques Universitaires Saint-Luc, UniversitAc Catholique de Louvain (UCLouvain), Brussels, Belgium

409

LONG-TERM SAFETY AND EFFICACY OF FITUSIRAN PROPHYLAXIS IN A PHASE 1/2 OPEN-LABEL EXTENSION STUDY IN PEOPLE WITH MODERATE OR SEVERE HEMOPHILIA A OR B
Steven W. Pipe¹, Toshko Lissitchkov², Sarah Mangles³, Pencho Georgiev⁴, Erin Feng⁵, Laurel A. Menapace⁶, Salim Kichou⁷, Shauna Andersson⁶, Marek Demissie⁶, Margaret Ragni⁸. ¹University of Michigan, Ann Arbor, MI, USA. ²Clinic Specialized Hospital for Active Treatment of Haematological Diseases, Sofia, Bulgaria. ³Haemophilia, Haemostasis and Thrombosis Centre, Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom. ⁴University Multiprofile Hospital for Active Treatment, Plovdiv, Bulgaria. ⁵Sanofi, Shanghai, China. ⁶Sanofi, Cambridge, MA, USA. ⁷Sanofi, Paris, France. ⁸University of Pittsburgh and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA

410

THROMBOELASTOMETRY (TEG): UTILITY IN DIAGNOSING OF INFECTION IN NEUROSURGERY INTENSIVE CARE UNIT (ICU) AS COMPARED TO ESTABLISHED BIOMARKERS
Renu Rani, Deepak Agarwal. AIIMS, New Delhi, India

411

FOURTH INTERIM ANALYSIS OF THE HEM-POWR STUDY: EVALUATING REAL-WORLD EFFECTIVENESS AND SAFETY OF DAMOCTOCOG ALFA PEGOL IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA A IN THE UNITED STATES
Mark T Reding¹, Beng Fuh², Vanessa Salinas³, Maissaa Janbain⁴. ¹University of Minnesota Medical Center, Minneapolis, MN, USA. ²East Carolina University, Greenville, NC, USA. ³Center for Inherited Blood Disorders, Orange, CA, USA. ⁴Tulane School of Medicine, New Orleans, LA, USA

412

EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A: SUMMARY OF 10 YEARS OF SAFETY DATA ON THROMBOEMBOLIC EVENTS AND THROMBOTIC MICROANGIOPATHY
Katayon Sarouei¹, Simona Barlera², Letizia Polito³, Guillermo Tobaruela³, Juliana M. L Biondo¹. ¹Genentech, Inc, South San Francisco, CA, USA. ²Parexel International, Milan, Italy. ³F. Hoffmann-La Roche Ltd, Basel, Switzerland

413

ACQUIRED VON WILLEBRAND SYNDROME IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: A FOCUS ON RESPONSE TO TREATMENT WITH IVIG
Tanna Tan¹, Rajiv K. K. Pruthi², Aneel A. Ashrani², Meera Sridharan². ¹Division of Internal Medicine, Mayo Clinic, Rochester, MN, USA. ²Division of Hematology/Oncology, Mayo Clinic, Rochester, MN, USA

414

TITLE: RECOMBINANT ADAMTS13 REPLACEMENT THERAPY IN A PEDIATRIC PATIENT WITH CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA.
Katrina` Unpingco¹, Michael F. Guerrera², Zahara Jones¹, Alison Matsunaga¹. ¹Hemophilia and Thrombosis Center UCSF Benioff Children's Hospitals, Oakland -San Francisco, CA, USA. ²Hemostasis and Thrombosis Center, Children's National Medical Center, Washington, DC, USA

A8. ANTITHROMBOTIC THERAPY

415

TIME TO STABLE THERAPEUTIC ANTICOAGULATION USING WEIGHT-BASED IV HEPARIN DOSING CLINICAL DECISIONS SUPPORT PROGRAM
Keri S. Kim, Jean Lee, Miranda Hart, John Garofalo, Jeffrey J. Mucksavage. University of Illinois Chicago College of Pharmacy, Chicago, IL, USA

416

MONITORING BIVALIRUDIN ANTICOAGULANT EFFECT BY THE ADDITION OF DILUTED THROMBIN TIME COMPARED TO ACTIVATED PARTIAL THROMBOPLASTIN TIME ALONE
Vadim Kostousov, Karen Bruzdoski, Jun Teruya. Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA

417

COMPARATIVE PROTAMINE SULFATE AND HEPA-REMOVE NEUTRALIZATION STUDIES IN POTENCY ADJUSTED PORCINE AND BOVINE HEPARIN
Emily Krupa, Debra Hoppensteadt-Moorman, Walter Jeske, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA

A9. INFORMATIONAL ABSTRACT (POSTER ONLY)

418

THE RISK OF RECURRENT VENOUS THROMBOEMBOLSIM AND HEMORRHAGE IN THE POSTPARTUM PATIENT REQURING ANTICOAGULATION
Thomas Kiebalo^{1, 2}, Ann Malinowski^{1, 4}, Jose Carvalho^{1, 5}, Nadine Shehata^{1, 2, 3}. ¹Mount Sinai Hospital, Toronto, ON, Canada. ²Department of Medicine, University of Toronto, Toronto, ON, Canada. ³Department of Hematology, University of Toronto, Toronto, ON, Canada. ⁴Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada. ⁵Department of Anesthesiology, University of Toronto, Toronto, ON, Canada

419

NOVEL THROMBOPHILIA- PROTHROMBIN BELGRADE VARIANT IN A MEXICAN FAMILY
Natalie/A Montanez^{1, 3}, Miguel/A Escobar^{1, 2, 3}. ¹University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Houston, TX, USA. ²University of Texas Health Science Center of Houston, McGovern Medical School, Department of Internal Medicine, Houston, TX, USA. ³Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA

420

&LDQUO;THERE IS SO MUCH POWER IN JUST BELIEVING SOMEONE&RDQUO;: UNDERSTANDING THE LIVED EXPERIENCES OF WOMEN WITH HEAVY VAGINAL BLOOD LOSS
Fartoon M Siad¹, Andrea Lausman², Carolyn Snider³, Martina Trinkaus¹, Filomena Meffe², Michelle Sholzberg ^{1, 4}. ¹Department of Medicine, University of Toronto, Toronto, ON, Canada. ²Department of Obstetrics and Gynecology, Toronto, ON, Canada. ³Division of Emergency Medicine, Toronto, ON, Canada. ⁴4Department of Laboratory Medicine and Pathobiology, St. Michaela, Toronto, ON, Canada

10:30 - 11:30 AM

SHORT TALKS

SHORT TALKS - BLEEDING BACK TO THE BASICS
Chair/Organizer: Bobby Lee, Kyumin Lee
Sheraton Ballroom I-II

10:30

GERMINAL CENTER AND NON-GERMINAL CENTER B CELL RESPONSE TO FACTOR VIII IN HEMOPHILIA A PATIENTS
Maya Maarouf¹, Ian Smith¹, Wallace H Baldwin¹, John F Healey¹, Ernest T Parker¹, Courtney Cox¹, Robert F Sidonio, Jr¹, Karen L Zimowski¹, Glaivy Batsuli², Bhavya S Doshi³, Shannon L Meeks¹, Seema R Patel¹. ¹Aflac Cancer and Blood Disorders Center, Childrena, Atlanta, GA, USA. ²Stanford University, Palo Alto, CA, USA. ³Department of Pediatrics, Division of Hematology, Childrena, Philadelphia, PA, USA

10:45

ENHANCED ACTIVATION OF FVIII POSITIVELY IMPACTS CLOT FORMATION IN VIVO USING HEMOPHILIA A MICE
Lacramioara Ivanciu^{1, 2}, Mettine H. A. Bos¹, Rodney M. Camire^{1, 2}. ¹The Children's Hospital of Philadelphia, Division of Hematology and the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Philadelphia, PA, USA. ²University of Pennsylvania, Department of Pediatrics, Philadelphia, PA, USA

11:00

INTRINSIC XASE LIGAND INTERACTIONS IMPACT FVIIIA REGULATION
John J Morris^{1, 2}, Nicole A Parsons², Robert J Davidson¹, Lindsey A George^{1, 2}. ¹Children's Hospital of Philadelphia, Philadelphia, PA, USA. ²University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA

11:15

PROCOAGULANT RESCUE OF HEMOPHILIA B CAUSING FACTOR IX VARIANTS BY FACTOR FVIII MIMETICS
Kyumin Lee^{1, 2}, Yani Suber^{1, 2}, Julia Q. Chau^{1, 2}, Sebastian E. Leyes Porello^{1, 2}, Bhavya S. Doshi^{1, 2}, Ben J. Samelson-Jones^{1, 2}. ¹The Childrena, Philadelphia, PA, USA. ²University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA

SHORT TALKS - INDUSTRY THROMBOSIS - NO CME
Chair/Organizer: Vinai Bhagirath, Amaya Llorente
Chicago Ballroom VII

10:30

SAFETY AND EFFICACY OF LONG-TERM TREATMENT OF TYPE 1 PLASMINOGEN DEFICIENCY PATIENTS WITH INTRAVENOUS PLASMINOGEN REPLACEMENT THERAPY
Amy D Shapiro¹, Heather McDaniel², Robert W Decker³, Jeremy Lorber³, Karen Thibaudeau⁴, Joseph M Parker⁵. ¹Indiana Hemophilia a Thrombosis Center, Indianapolis, IN, USA. ²Vanderbilt University, Nashville, TN, USA. ³Cedars Sinai Medical Center, Los Angeles, CA, USA. ⁴Kedrion, Laval, Canada. ⁵Kedrion, Fort Lee, NJ, USA

10:45

EFFICACY AND SAFETY IS MAINTAINED IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RECEIVING PEGCETACOPLAN FOR UP TO 3 YEARS
Carlos de Castro¹, Brian Mulherin^{2, 3}, Christopher J. Patriquin⁴, Veena Selvaratnam⁵, Raymond Siu Ming Wong⁶, Richard J. Kelly⁷, Lisa Tan^{8, 9}, Peter Hillmen¹⁰, Dale Zhang¹⁰, Regis Peffault de Latour^{11, 12}. ¹Duke University, Durham, NC, USA. ²Hematology Oncology of Indiana, Indianapolis, IN, USA. ³Ascension St. Vincent Carmel, Carmel, IN, USA. ⁴University Health Network, Toronto, ON, Canada. ⁵Ampang Hospital, Ampang, Malaysia. ⁶The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong. ⁷Department of Haematology, St. Jamesa, Leeds, United Kingdom. ⁸Swedish Orphan Biovitrum AB, Stockholm, Sweden. ⁹Lisa Tan Pharma Consulting Ltd, Cambridge, United Kingdom. ¹⁰Apellis Pharmaceuticals, Inc, Waltham, MA, USA. ¹¹French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Paris, France. ¹²UniversitAc Paris CitAc, Paris, France

11:00

TOLERABILITY AND PHARMACODYNAMIC EFFECT OF REGN9933, A MONOCLONAL ANTIBODY DIRECTED AGAINST THE FACTOR XI APPLE 2 DOMAIN: RESULTS FROM A FIRST-IN-HUMAN STUDY
Ethan Marin¹, Guixian Lin¹, Hisham Abdallah¹, David Gutstein¹, Andrew Kordahi², Karoline Meagher¹, Frederic Cauwberghs³. ¹Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA. ²Regeneron Pharmaceuticals, Inc. (at time of study), Tarrytown, NY, USA. ³SGS (at time of study), Antwerp, Belgium

11:15

SAFETY AND EFFICACY OF VALOCTOCOGENE ROXAPARVOVEC GENE TRANSFER FOR SEVERE HEMOPHILIA A: AN UPDATE FROM 4 YEARS AFTER TREATMENT
Andrew D Leavitt¹, Johnny Mahlangu², Emily Symington³, Doris V Quon⁴, Adam Giermasz⁵, Nigel S Key⁶, Steven W Pipe⁷, Bella Madan⁸, Sheng-Chieh Chou⁹, Robert Klamroth^{10, 11}, Jane Mason¹², Flora Peyvandi^{13, 14}, Hua Yu¹⁵, Tara M Robinson¹⁵, Margareth C Ozelo¹⁶. ¹Adult Hemophilia Treatment Center, University of California San Francisco, San Francisco, CA, USA. ²Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand and NHLS, Johannesburg, South Africa. ³Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom. ⁴Orthopaedic Hemophilia Treatment Center, Los Angeles, CA, USA. ⁵Hemophilia Treatment Center, University of California Davis, Sacramento, CA, USA. ⁶UNC Blood Research Center, University of North Carolina, Chapel Hill, NC, USA. ⁷Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA. ⁸Guya, London, United Kingdom. ⁹Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. ¹⁰Vascular Medicine and Haemostaseology, Vivantes Klinikum im Friedrichshain, Berlin, Germany. ¹¹Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany. ¹²Queensland Haemophilia Centre, Cancer Care Services, Royal Brisbane and Womena, Brisbane, Australia. ¹³Fondazione IRCCS Caa, Milan, Italy. ¹⁴UniversitAn degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy. ¹⁵BioMarin Pharmaceutical Inc, Novato, CA, USA. ¹⁶Hemocentro UNICAMP, Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, Brazil

SHORT TALKS - TAKING LAB MONITORING TO THE NEXT LEVEL
Chair/Organizer: Kristi Smock, Prarthana Parthasarathy
Sheraton Ballroom IV-V

10:30

FACTOR II AND X (FIIX) MONITORED WARFARIN IS MORE EFFECTIVE THAN PT-INR MONITORED WARFARIN AND DIRECT ORAL ANTICOAGULANTS IN PATIENTS ANTICOAGULATED LONG-TERM FOR NON-VALVULAR ATRIAL FIBRILLATION. THE GREATER REYKJAVIK ORAL ANTICOAGULATION (GROAC) STUDY.
Arnar B. Ingason^{1, 2}, Brynja R. Gudmundsdottir¹, Ragnar Palsson^{1, 3, 4}, Arnar S. Agustsson¹, Edward Rumba¹, Daniel A. Palsson¹, Indridi Reynisson¹, Sigrun H. Lund⁵, Johann P. Hreinsson⁶, Einar S. Bjornsson^{1, 5}, Pall T. Onundarson^{1, 5}. ¹Landspitali National University Hospital, Reykjavik, Iceland. ²University of Vermont, Burlington, VT, USA. ³Massachusetts General Hospital, Boston, MA, USA. ⁴Harvard University, Boston, MA, USA. ⁵University of Iceland, Reykjavik, Iceland. ⁶Sahlgrenska University, Gothenburg, Sweden

10:45

DROP-OF-BLOOD COAGULATION ANALYSIS BY I-QATTTM
Huy Q Pham¹, Collette Barnor¹, Daishen Luo¹, Elizabeth M Cummins¹, Nithya Kasireddy¹, Daniel Arango², Shaun Yockelson³, Damir B Khismatullin¹. ¹Department of Biomedical Engineering, Tulane University, New Orleans, LA, USA. ²The University of Texas Medical Branch, Galveston, TX, USA. ³Department of Anesthesiology and Perioperative Medicine, Ochsner Medical Center, New Orleans, LA, USA

11:00

REAL-WORLD USE AND CORRELATION BETWEEN PLATELET-DEPENDANT ACTIVITY ASSAYS OF VON WILLEBRAND FACTOR (VWF):AB AND VWF:GP1BM IN PATIENTS WITH VON WILLEBRAND DISEASE IN THE AGE OF THE NEW GUIDELINES: A SINGLE-CENTER STUDY
Prarthana Parthasarathy, Kerry M Hege. Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, IN, USA

11:15

ICOAGLAB PERMITS COMPREHENSIVE COAGULATION PROFILING IN PATIENTS ON PERCUTANEOUS CARDIAC PUMP SUPPORT
Eli J Foster, Nathaniel Hai, Ziqian Zeng, Seemantini K Nadkarni. Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

11:45 - 12:45 PM

SATELLITE SYMPOSIUM

THE ROLE OF THE LIVER IN HEMOPHILIA GENE THERAPY & CLINICAL IMPLICATIONS (SPONSORED BY PFIZER)
Chicago Ballroom VI

The advent of liver directed-gene therapies in hemophilia has placed increasing interest on liver health in the pre and post infusion settings. This session will explore the role of the liver in hemophilia gene therapy including evaluation of liver heath and key considerations for clinical management from a hepatologists perspective.

VONVENDI PROPHYLAXIS FOR SEVERE TYPE 3 VON WILLEBRAND DISEASE - PATIENT CASE DISCUSSION (SPONSORED BY TAKEDA PHARMACEUTICALS)
Chicago Ballroom IX-X

Join our expert HCP and a patient living with von Willebrand Disease (VWD) for an interactive journey. Our panel will guide you through the patients experience with VWD, review their treatment history, and discuss how VONVENDI may be added to the treatment plan for prophylaxis.

12:45 - 1:30 PM

POSTERS/EXHIBITS/BREAK

POSTERS/EXHIBITS/BREAK (click to view) (click to close)
Riverwalk AB

A4. DISORDERS OF PLATELET NUMBER OR FUNCTION

502

EVALUATION OF ANTICOAGULATION MANAGEMENT IN PATIENTS WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA AWAITING DIAGNOSIS CONFIRMATION
Alyssa R. George, Katelyn Sylvester, Dareen Kanaan, Delaney Corcoran, Kenneth Lupi, Brian Schuler, Jean M. Connors. Brigham and Women's Hospital, Boston, MA, USA

503

NATURAL HISTORY OF BLEEDING, TRANSFUSION, AND ANTIBODY PREVALENCE IN A SUBSET OF HERMANSKY-PUDLAK SYNDROME PATIENTS: EFFECTS OF FREEZE-DRIED LYOPHILIZED PLATELET DERIVED HEMOSTAT EX VIVO
Keith Moskowitz, Michael Fitzpatrick, Lisa Booth, Maria Abreau-Blanco, Matthew Dickerson, Anna Yu, Anya Derbij, W. Allan Alexander. Cellphire Therapeutics, Inc, Rockville, MD, USA

A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS

504

CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL TREATMENT IN VERY HIGH TITER INHIBITOR MURINE MODEL REQUIRES CD19 AND BCMA TARGETING
Julia Q. Chau², Caroline Markmann¹, Zheng Zhang¹, Michael C. Milone¹, Bhavya S. Doshi^{2, 3}, Vijay G. Bhoj¹, Benjamin J. Samelson-Jones^{2, 3}. ¹Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ²The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. ³Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

505

NORMALIZATION OF THROMBIN GENERATION RESULTS USING WITHIN-RUN PLASMA NORMALIZATOR SIMULTANEOUSLY.
Loic J. Letertre^{1, 2}, Pall T. Onundarson¹, Jon T. Bergthorsson^{1, 2}. ¹Landspitali - The National University Hospital, Reykjavik, Iceland. ²The University of Iceland, Reykjavik, Iceland

506

TWO-CENTER EXTERNAL VALIDATION OF A MACHINE LEARNING NATURAL LANGUAGE PROCESSING (NLP) ALGORITHM FOR VENOUS THROMBOEMBOLISM (VTE) ASCERTAINMENT
Shengling Ma¹, Omid Jafari¹, Arash Maghsoudi¹, Jennifer La^{2, 3}, Emily Zhou⁴, Iuliia Kovalenko⁵, Steven Horng^{3, 6}, Nathanael Fillmore^{2, 3}, Ang Li¹, Barbara Lam⁶. ¹Baylor College of Medicine, Houston, TX, USA. ²VA Boston Healthcare System, Boston, MA, USA. ³Harvard Medical School, Boston, MA, USA. ⁴University of Texas Health Science Center at Houston, Houston, TX, USA. ⁵UPMC Harrisburg, Harrisburg, PA, USA. ⁶Beth Israel Deaconess Medical Center, Boston, MA, USA

A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS

507

CHILD HEMO-TEM OBSERVER-REPORTED OUTCOME MEASURE: UNDERSTANDING AND ASSESSING TREATMENT BURDEN IN CHILDREN WITH HEMOPHILIA
Meryl Brod¹, Donald M. Bushnell², Jesper Skov Neergaard³, Anne Kirstine Busk³, Vlady Ostrow⁴. ¹The Brod Group, Mill Valley, CA, USA. ²Evidera|PPD, Bethesda, MD, USA. ³Novo Nordisk A/S, SAcborg, Denmark. ⁴Novo Nordisk Inc, Plainsboro, NJ, USA

508

LONG-TERM EVALUATION OF LIVER HEALTH IN PARTICIPANTS WHO RECEIVED FIDANACOGENE ELAPARVOVEC: DATA FROM A PHASE 1/2A STUDY WITH UP TO 6 YEARS OF FOLLOW UP
Jonathan Ducore¹, Lindsey A George², Ben J Samelson-Jones², John Rasko³, Catherine McGuinn⁴, Adam Giermasz¹, Jerome Teitel⁵, Katherine High⁶, Jeremy Rupon⁷, Annie Fang⁷, Lynne Smith⁷, Priya Patel⁷, Amit Chhabra⁷, Frank Plonski⁷, Matko Kalac⁷. ¹UC David Comprehensive Cancer Center, Sacramento, CA, USA. ²Childrena, Philadelphia, PA, USA. ³Centenary Institute, Sydney, Australia. ⁴Weill Cornell Medical Center, New York, NY, USA. ⁵University of Toronto, Toronto, ON, Canada. ⁶University of Pennsylvania, Philadelphia, PA, USA. ⁷Pfizer Inc, New York, NY, USA

509

EMICIZUMAB FOR SEVERE VON WILLEBRAND DISEASE (VWD) AND VWD/HEMOPHILIA A: THE EMIVWD STUDY
Jonathan Roberts^{1, 2}, MIchael Tarantino^{1, 2}. ¹Bleeding a Clotting Disorders Institute, Peoria, IL, USA. ²Departments of Pediatrics and Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA

510

DESIGN OF A PROSPECTIVE, OBSERVATIONAL, MULTICENTER STUDY OF THE EFFECTIVENESS OF EFANESOCTOCOG ALFA ON LONG-TERM JOINT HEALTH IN PATIENTS WITH HEMOPHILIA A IN THE UNITED STATES AND JAPAN
Jonathan C. Roberts¹, Spencer Sullivan², Eric F. Grabowski³, Doris Quon⁴, Jennifer Dumont⁵, Annemieke Willemze⁶, Nicole Tsao⁵. ¹Bleeding a Clotting Disorders Institute, Peoria, IL, USA. ²Mississippi Center for Advanced Medicine, Madison, MS, USA. ³Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. ⁴Orthopedic Hemophilia Treatment Center, Los Angeles, CA, USA. ⁵Sanofi, Cambridge, MA, USA. ⁶Sanofi, Amsterdam, Netherlands

511

SEROPREVALENCE AND SEROCONVERSION AMONG PEOPLE WITH HEMOPHILIA A IN THE UNITED STATES: OBSERVATIONS FROM THE SAAVY (SEROPREVALENCE OF AAV ANTIBODY) STUDY
Amy Shapiro¹, Leonard A. Valentino^{2, 3}, David Hinds⁴, Manil Vaghela⁵, Erin Goodman⁴, Karim Iskander⁴, George Dela Cerda ⁴, Kim Schafer⁶, Steven Pipe⁷. ¹Indiana Hemophilia Thrombosis Center, Indianapolis, IN, USA. ²National Bleeding Disorders Foundation, New York, NY, USA. ³Rush University, Chicago, IL, USA. ⁴BioMarin Pharmaceutical, Novato, CA, USA. ⁵BioMarin Pharmaceutical, London, United Kingdom. ⁶Hemostasis and Thrombosis Center, UC Davis Health, Sacramento, CA, USA. ⁷Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA

512

REAL-WORLD DATA ON EMICIZUMAB PROPHYLAXIS IN OLDER PERSONS WITH HEMOPHILIA A: A RETROSPECTIVE SINGLE CENTER COHORT STUDY
Shalini Vemuru¹, Stacey Fedewa^{2, 3}, Christine Kempton^{2, 3}. ¹Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA, USA. ²Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA. ³Hemophilia of Georgia Center for Bleeding a Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA, USA

513

CLINICAL UTILITY AND PERFORMANCE OF VON WILLEBRAND FACTOR ACTIVITY ASSAYS IN A NATIONAL REFERENCE LABORATORY: THE VITALANT COAGULATION LABORATORY'S EXPERIENCE WITH THE RISTOCETIN COFACTOR AND VWF:GP1BM ASSAYS
Angela Verdoni¹, Mason Marshall², Irina Chibisov¹. ¹Vitalant Coagulation Laboratory, Pittsburgh, PA, USA. ²Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA

514

BRAIN VOLUMES AND NEUROCOGNITIVE OUTCOMES IN CHILDREN WITH HEMOPHILIA A
Silvia Verhofste¹, Ahmad Al-Huniti^{1, 2}, Marci Novak¹, Amy L. Conrad^{1, 5, 6}, Ellen van der Plas^{3, 4}, Lyndsay Harshman^{1, 5, 6}, Janice M. Staber^{1, 5, 6}. ¹Stead Family Department of Pediatrics, University of Iowa, Iowa City, IA, USA. ²*Current Location - Mayo Clinic, Rochester, MN, USA. ³Department of Psychiatry, University of Iowa, Iowa City, IA, USA. ⁴*Current Location -University of Arkansas for Medical Sciences, Pediatrics Arkansas Children's Hospital, Hematology/Oncology, Little Rock, AR, USA. ⁵The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, IA, USA. ⁶Iowa Neuroscience Institute, Iowa City, IA, USA

A8. ANTITHROMBOTIC THERAPY

515

SINGLE CENTER RETROSPECTIVE COMPARISON OF BIVALIRUDIN AND HEPARIN FOR THERAPEUTIC ANTICOAGULATION IN PEDIATRIC PATIENTS
Clayton Habiger, Shannon Carpenter. Children's Mercy Hospital, Kansas City, MO, USA

516

TRANSITIONING FROM ORAL FACTOR XA INHIBITOR TO UNFRACTIONATED HEPARIN USING HEPARIN-CALIBRATED ANTI-XA LEVELS
Mahnoor M Khan¹, Magdalena E Jasinska², Jeremy P Kosacz³, Erin N Robinson¹, Lisa M Thompson³, Brandon Pierce³, Anne E Rose¹. ¹UW Health - Madison, Madison, WI, USA. ²University of Wisconsin School of Pharmacy, Madison, WI, USA. ³UW Health - Northern Illinois, Rockford, IL, USA

517

COVID-19 VENOUS THROMBOEMBOLISM PROPHYLAXIS GUIDELINES
Sara McElroy^{1, 2}, Emily Cramer^{1, 2}, Lauren Amos^{1, 2}. ¹Children's Mercy Kansas City, Kansas City, MO, USA. ²University of Missouri-Kansas City, Kansas City, MO, USA

A9. INFORMATIONAL ABSTRACT (POSTER ONLY)

518

BENEFIT OF ALBUMIN INFUSION IN AN ELDERLY CIRRHOTIC PATIENT ON DOAC: ABOUT A CASE .
LAMIA AIT OUALI¹, FARID SLIMANI², SAMIA OULARBI¹, SAMIR TINE^{1, 3}. ¹APHP RenAc Muret, Sevran, France. ²APHP Jean Verdier, Bondy, France. ³APHP Avicenne, Bobigny, France

519

THE SEVERE VON WILLEBRAND DISEASE PATIENT REGISTRY: A LONGITUDINAL NATURAL HISTORY AND PATIENT OUTCOMES STUDY
Johnna Cesta¹, Mrinal Gounder¹, Christopher Walsh ², Alice Araphsian¹, Jeanette Cesta¹, Christina Morgenthaler¹. ¹VWD Connect Foundation, Wellington, FL, USA. ²Icahn School of Medicine Mount Sinai Hospital, New York, NY, USA

520

EFFECT OF DOAC STOP ON COAGULATION FACTOR ACTIVITY LEVELS
Dan A Stephens¹, Ronda A Crist¹, Karen A Moser¹, Allison Carey^{1, 2}, Abdulrahman Saadalla^{1, 2}, Kristi J Smock^{1, 2}. ¹ARUP Laboratories Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA. ²University of Utah Department of Pathology, Salt Lake City, UT

1:30 - 2:45 PM

PLENARY SESSION

ABORTION/REPRODUCTIVE HEALTH - WHEN THE LAW AND HEALTHCARE COLLIDE - HOW LAWS THAT RESTRICT ACCESS TO REPRODUCTIVE CARE ARE AFFECTING HEMOSTASIS AND THROMBOSIS PATIENTS
Chair/Organizer: Julie Jaffray, Vinai Bhagirath
Sheraton Ballroom IV-V

1:30

EFFECT ON STEM CELL RESEARCH
Paul Blumenthal .

1:55

POST-ROE'S DOWNSTREAM EFFECTS - IMPACTING PATIENTS, PERSONNEL & TRAINEES
Alyssa Colwill.

2:20

IMPACT ON CLINICAL CARE THROMBOSIS AND HEMOSTASIS
Jeff Federspiel.

3:00 - 4:30 PM

THROMBOSIS

CLINICAL CHALLENGES FOR ANTITHROMBOTIC MANAGEMENT IN THE AMBULATORY CARE SETTING
Chair/Organizer: Anne Rose, Leo Brandao
Sheraton Ballroom IV-V

3:00

DE-ESCALATING ANTITHROMBOTIC THERAPY: HOW DO WE ENSURE APPROPRIATE USE
Cynthia Fenton.

3:30

PERIOPERATIVE CONSIDERATIONS FOR ANTICOAGULATION WITH MECHANICAL DEVICES AND HEART VALVES
James Douketis.

4:00

KEEPING ANTICOAGULATION CLINICS RELEVANT IN THE NEXT DECADE
Kelly Rudd.

3:00 - 4:30 PM

LABORATORY / BASIC SCIENCE

IMMUNOTHROMBOTIC SYNDROMES
Chair/Organizer: Cathy Hayward, Kristi Smock
Chicago Ballroom VII

3:00

MACHINE LEARNING FOR HIT
Adam Cuker.

3:30

IMMUNOTHROMBOSIS AND SEPTICEMIA
Alison Fox-Robichaud.

4:00

COMPLEMENT ACTIVATION BY HIT IMMUNE COMPLEXES
Sanjay Khandelwal.

3:00 - 4:30 PM

HEMOSTASIS

OUCH! PAIN AND BLEEDING DISORDERS
Chair/Organizer: Bethany Samuelson Bannow, Allison Wheeler
Sheraton Ballroom I-II

3:00

BIOPSYCHOSOCIAL PAIN MECHANISMS
Kalpna Gupta.

3:30

INTERDISCIPLINARY PAIN ASSESSMENT
Tyler Buckner.

4:00

BARRIERS AND SUCCESSES TO IMPLEMENTING INTERDISCIPLINARY MULTIMODAL PAIN MANAGEMENT
Lena Volland.

4:30 - 5:15 PM

POSTERS/EXHIBITS/BREAK

POSTERS/EXHIBITS/BREAK (click to view) (click to close)
Riverwalk AB

A2. PLATELET ACTIVATION AND BIOCHEMISTRY

601

IL-6-INDUCED POTENTIATION OF PLATELET ACTIVITY AND GLYCOSYLATION IN VENOUS THROMBOEMBOLISM
Michelle K. Brenner¹, Karin Hoffmeister², Brian Branchford¹. ¹Pediatric Hematology/Oncology/Bone Marrow Transplant, Childrena, Milwaukee, WI, USA. ²Translational Glycomics Center, Versiti Blood Research Institute, Milwaukee, WI, USA

A3. VASCULAR WALL BIOLOGY, ENDOTHELIAL PROGENITOR CELLS AND PLATELET ADHESION

602

PLATELET-NUCLEIC ACID RECEPTOR PROMOTES PULMONARY THROMBO-INFLAMMATION IN SICKLE CELL DISEASE
Rikesh K. Dubey¹, Omika Katoch¹, Prithu Sundd^{1, 2}. ¹Thrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI, USA. ²Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA

A4. DISORDERS OF PLATELET NUMBER OR FUNCTION

603

ATHN TRANSCENDS: NATURAL HISTORY COHORT STUDY OF BLEEDING SYMPTOMS AND TREATMENT OUTCOMES IN PATIENTS WITH GLANZMANN THROMBASTHENIA
Divyaswathi Citla Sridhar¹, Sanjay Ahuja², Tammuella Chrisentery-Singleton³, Carrie O'Neil³, Catherine Rea⁴, Jigar Amin⁴, Mike Recht^{5, 6}, Meera Chitlur⁷. ¹Arkansas Childrena, Little Rock, AR, USA. ²Rainbow Babies a Childrena, Cleveland, OH, USA. ³American Thrombosis and Hemostasis Network, Rochester, NY, USA. ⁴Hemab Therapeutics, Cambridge, MA, USA. ⁵National Bleeding Disorders Foundation, New York, NY, USA. ⁶Yale University School of Medicine, New Haven, CT, USA. ⁷Central Michigan University/Childrena, Detroit, MI, USA

604

ANTI-GPIBα ANTIBODIES IN FNAIT ARE ASSOCIATED WITH RECURRENT MISCARRIAGES
Christopher J. Khoury^1-3, Pingguo Chen^1-4, Guangheng Zhu^{2, 3}, Zoya Tawhidi^1-3, Alan H. Lazarus^{1-4, 8}, Yiming Wang⁵, Karen Chong⁶, David Chitayat^{1, 6}, Heyu Ni^{1-4, 7, 8}. ¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. ²Keenan Research Centre for Biomedical Science of St. Michaela, Toronto, ON, Canada. ³Toronto Platelet Immunology Group, Toronto, ON, Canada. ⁴Canadian Blood Services Centre for Innovation, Toronto, ON, Canada. ⁵Division of Clinical and Metabolic Genetics, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. ⁶The Prenatal Diagnosis and Medical Genetics Program, Department of Obstetrics and Gynecology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada. ⁷Department of Physiology, University of Toronto, Toronto, ON, Canada. ⁸Department of Medicine, University of Toronto, Toronto, ON, Canada

605

UTILITY OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING (TEG-PM) FOR MONITORING PLATELET TRANSFUSION IN QUALITATIVE PLATELET DISORDERS
Robert H. Lee^{1, 2}, Tanvi Rudran², Wolfgang Bergmeier^{1, 2}. ¹Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ²UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS

606

TITLE: REAL-WORLD EFFICACY DATA ON ADOLESCENT HEMOPHILIA A PATIENTS TRANSITIONING TO BAY 81-8973 OR BAY 94-9027 IN THE ATHNDATASET
Martin Chandler¹, Jessica Charlet², Thomas Moulton², Michael Recht^{3, 4}. ¹American Thrombosis a Hemostasis, Rochester, NY, USA. ²Bayer Pharmaceuticals, USA, Whippany, NJ, USA. ³National Bleeding Disorders Foundation, New York City, NY, USA. ⁴Yale University School of Medicine, New Haven, CT, USA

A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS

607

BURDEN OF DISEASE AND IMPACT ON QUALITY OF LIFE IN HEREDITARY FACTOR X DEFICIENCY PATIENTS WHO WERE DIAGNOSED AT BIRTH: FINDINGS FROM THE HEREDITARY FACTOR X DEFICIENCY IN AMERICA SURVEY
Kim Clark¹, Amy Wu², Denise A. Garner², Lorie Mody², Jaymin Patel², Brian Branchford³. ¹Kedrion Biopharma, INC, Fort Lee, NJ, USA. ²AESARA, INC, Chapel Hill, NC, USA. ³Versiti Blood Research Institute, Medical College of Wisconsin, and Children's Wisconsin, Milwaukee, WI, USA

608

REBLEED INCIDENCE WITH EPTACOG BETA TREATMENT THROUGH 24 AND 48 HOURS IN CHILDREN (UNDER 12 YEARS) WITH HEMOPHILIA A OR B WITH INHIBITORS
Amy L. Dunn¹, Manuel Carcao², Meera Chitlur³, Joanna Davis⁴, Nina Hwang⁵, Craig Kessler⁶, Catherine McGuinn⁷, Danielle Nance⁸, Robert Sidonio Jr. ⁹, Tammuella Chrisentery-Singleton¹⁰, Courtney D. Thornburg^{11, 12}, Michael Wang¹³, Steven Pipe¹⁴. ¹Nationwide Childrena, Columbus, OH, USA. ²The Hospital for Sick Children, Toronto, ON, Canada. ³Central Michigan University College of Medicine/Childrena, Detroit, MI, USA. ⁴Pediatric Hemophilia Treatment Center, University of Miami, Miami, FL, USA. ⁵Center for Inherited Blood Disorders, Orange, CA, USA. ⁶Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. ⁷Department of Pediatrics, Division of Pediatric Hematology/Oncology, Weill Cornell Medicine, New York, NY, USA. ⁸Banner MD Anderson Cancer Center, Gilbert, AZ, USA. ⁹Aflac Cancer and Blood Disorders Center and Emory University, Atlanta, GA, USA. ¹⁰American Thrombosis and Hemostasis Network, Rochester, NY, USA. ¹¹Hemophilia and Thrombosis Treatment Center, Rady Children's Hospital-San Diego, San Diego, CA, USA. ¹²Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, USA. ¹³Hemophilia and Thrombosis Center, University of Colorado, Aurora, CO, USA. ¹⁴University of Michigan, Ann Arbor, MI, USA

609

RECURRENT PREGNANCY LOSS IN TYPE 3 VON WILLEBRAND DISEASE WITH A UNIQUE MUTATION PROFILE
Amanda D. Kaveney, Claire Philipp. Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA

610

VALUE OF FUNCTIONAL PROTEIN S ACTIVITY ASSAYS FOR DETECTION OF TYPE II PROTEIN S DEFICIENCY
Katharine A. Marsden, Shelbey Bauman, Peter F. Mannion, Morayma Reyes Gil. Cleveland Clinic Foundation, Cleveland, OH, USA

611

VALIDATING THE JAKPOT PREDICTION RULE FOR IDENTIFYING WHICH PATIENTS WITH ERYTHROCYTOSIS ARE UNLIKELY TO HAVE A JAK2 MUTATION
Kevin O'Sullivan¹, Roosevelt Lu¹, Jason A Freed¹, George Goshua², Justine Ryu², Rushad Patell¹, Barbara D Lam¹. ¹Beth Israel Deaconess Medical Center, Boston, MA, USA. ²Yale Medical Center, New Haven, CT, USA

612

CLINICAL OUTCOMES IN MILD-MODERATE AND SEVERE PATIENTS WITH HEMOPHILIA B: RESULTS FROM A REAL-WORLD, MULTI-NATIONAL SURVEY
Sheena Thakkar¹, Lisa Wilcox¹, Valeria Merla¹, Anna Kane¹, Jose Alvir¹, Surya Pemmaraju¹, Jennifer Mellor², Ella Morton², Jade Garratt Wheeldon², James Pike², Nathan Ball², Stevie Olsen². ¹Pfizer Inc, New York, NY, USA. ²Adelphi Real World, Bollington, United Kingdom

613

OUTCOMES IN NORTH AMERICAN PARTICIPANTS WHO RECEIVED EFANESOCTOCOG ALFA PROPHYLAXIS IN THE XTEND-1 STUDY
Annette von Drygalski¹, Tung Wynn², Doris Quon³, Anthony KC Chan⁴, Angela C Weyand⁵, Davide Matino⁶, Jennifer Dumont⁷, Andrew Wilson⁷, Umer Khan⁸, Sriya Gunawardena⁹. ¹Division of Hematology/Oncology, Department of Medicine, University of California San Diego, San Diego, CA, USA. ²Department of Pediatrics, University of Florida, Gainesville, FL, USA. ³Luskin Orthopaedic Institute for Children, Los Angeles, CA, USA. ⁴Department of Pediatrics, McMaster Childrena, Hamilton, ON, Canada. ⁵Division of Hematology/Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA. ⁶Division of Hematology a Thromboembolism, Department of Medicine, McMaster University, Hamilton, ON, Canada. ⁷Sanofi, Cambridge, MA, USA. ⁸Sanofi, San Diego, CA, USA. ⁹Sanofi, Bridgewater, NJ, USA

614

HEALTH-RELATED QUALITY OF LIFE AND TREATMENT BURDEN IN PATIENTS WITH HEMOPHILIA A/B WITHOUT INHIBITORS ON CONCIZUMAB PROPHYLAXIS: RESULTS FROM THE PHASE 3 EXPLORER8 STUDY
Guy Young¹, Gary Benson², Hermann Eichler³, Johnny Mahlangu⁴, Jesper Skov Neergaard⁵, Jan Odgaard-Jensen⁵, Jay Jay Thaung Zaw⁵, Jameela Sathar⁶, Huyen Tran⁷, Tadashi Matsushita⁸, Emily K. Waters⁹. ¹Hemostasis and Thrombosis Center, Childrena, Los Angeles, CA, USA. ²Department of Hematology, Belfast Health and Social Care Trust, Belfast, Ireland. ³Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and University Hospital, Homburg, Saar, Germany. ⁴Department of Molecular Medicine and Haematology, School of Pathology, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa. ⁵Novo Nordisk A/S, SAcborg, Denmark. ⁶Department of Haematology, Ampang Hospital, Selangor, Malaysia. ⁷Ronald Sawers Haemophilia Treatment Centre, Monash University, Melbourne, Australia. ⁸Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan. ⁹Novo Nordisk Inc, Plainsboro, NJ, USA

A8. ANTITHROMBOTIC THERAPY

615

ANTICOAGULANT MANAGEMENT OF CANCER-ASSOCIATED THROMBOSIS AND THROMBOCYTOPENIA: A RETROSPECTIVE CHART REVIEW
Umaima Abbas¹, Ushra Khan¹, Robin Mackenzie¹, Rija Fatima², Tzu-Fei Wang³, Caroline Hamm^{1, 4, 5}, Andrea Cervi^{1, 4, 5}. ¹Schulich School of Medicine a Dentistry, University of Western Ontario, London, ON, Canada. ²Department of Translational Health Science, University of Windsor, Windsor, ON, Canada. ³Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON, Canada. ⁴Department of Biomedical Sciences, University of Windsor, Windsor, ON, Canada. ⁵Windsor Regional Hospital, Windsor, ON, Canada

616

A SURVEY OF CLINICIAN PRACTICE PATTERNS ON THE USE OF INFERIOR VENA CAVA FILTERS FOR VENOUS THROMBOEMBOLISM
Jillian Calandra¹, Rahman Ladak², Massimo Sementilli³, Alejandro Lazo-Langner^{2, 4}, Deborah Siegal^{5, 6}, Tzu-Fei Wang^{5, 6}, Rong Luo⁷, Andrea Cervi⁷. ¹WE-SPARK Health Institute, Windsor, ON, Canada. ²Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada. ³Department of Biomedical Sciences, University of Windsor, Windsor, ON, Canada. ⁴Lawson Health Research Institute, London, ON, Canada. ⁵Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. ⁶Ottawa Hospital Research Institute, Ottawa, ON, Canada. ⁷Windsor Regional Hospital, Windsor, ON, Canada

617

INR ABOVE FIVE WARFARIN EVENTS INPATIENT REQUIRE FOCUS ON PREVENTABLE CASES TO LOWER INCIDENCE
Benjamin/J Jung¹, Lisa Baumann-Kreuziger^{1, 2}, Garret Newkirk¹. ¹Froedtert and Medical College of Wisconsin, MIlwaukee, WI, USA. ²Versiti Blood Center of Wisconsin, Milwaukee, WI, USA

A9. INFORMATIONAL ABSTRACT (POSTER ONLY)

618

EVALUATION OF NURSE-MANAGED HEPARIN NOMOGRAM ADHERENCE AFTER IMPLEMENTATION OF AN ELECTRONIC MEDICAL RECORD-EMBEDDED HEPARIN CALCULATOR
Taylor Robichaux¹, John Lindsley¹, Vi Gilmore¹, Rosemary Duncan¹, Catherine Kiruthi¹, Erica Willits², Michael Streiff³, Rakhi Naik³, Jennifer Yui³, Kathryn Dane¹. ¹Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, USA. ²Department of Nursing, The Johns Hopkins Hospital, Baltimore, MD, USA. ³Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

619

A COMPARISON OF TARGETED HIGH-RANGE VERSUS LOW-RANGE ANTI-XA GOAL FOR INTRAVENOUS UNFRACTIONATED HEPARIN IN PATIENTS WITH MECHANICAL CIRCULATORY SUPPORT DEVICES
Yue Wang, Long To, Mathew Jones, Kristin Griebe. Henry Ford Hospital, Detroit, MI, USA

5:15 - 6:45 PM

THROMBOSIS / HEMOSTASIS

ANTICOAGULATION FOR PATIENTS WITH BLEEDING RELATED CONDITIONS
Chair/Organizer: Vinai Bhagirath, Bethany Samuelson Bannow
Sheraton Ballroom I-II

5:15

ANTICOAGULANTS IN PATIENTS WITH BLEEDING DISORDERS
Bethany Samuelson Bannow.

5:45

DESCRIBING THE RISKS FOR BLEEDING AND THROMBOSIS UNIQUE TO PATIENTS WITH RENAL IMPAIRMENT
William Dager.

6:15

RESUMPTION OF ANTICOAGULATION POST BLEEDING EVENT
Dan Witt.

5:15 - 6:45 PM

BASIC SCIENCE

CUTTING TO THE CHASE- FIBRINOLYSIS
Chair/Organizer: Jordan Shavit, Maya Maarouf
Sheraton Ballroom IV-V

5:15

ENGINEERING DEVICES TO MEASURE AND/OR ENHANCE FIBRINOLYSIS
Dante Disharoon.

5:45

TFPI AS A MODIFIER OF FIBRINOLYSIS AND BLEEDING IN FXI DEFICIENCY
Stephanie Reitsma.

6:15

INTERSECTION OF FIBRIN(OLYSIS) AND INFLAMMATION AT THE ORAL MUCOSA BARRIER
Lakmali Silva.

5:15 - 6:45 PM

LABORATORY

DISSOLVING THE CLOT OF THROMBILIA TESTING: CURRENT DIAGNOSTIC UPDATES AND CHALLENGES
Chair/Organizer: Karen Moser, Rae Kerlin
Chicago Ballroom VII

5:15

UPDATES ON PROTEIN C AND PROTEIN S DEFICIENCY TESTING (HIGHLIGHTS AND CRITIQUES OF RECENT ISTH DOCUMENTS)
Marian Rollins-Raval.

5:45

CHALLENGES IN PRACTICAL APPLICATION OF LA TESTING GUIDELINES IN NORTH AMERICA: MIXING STUDIES AND BEYOND!
Jacqueline Poston, Andrew Goodwin.

6:15

PITFALLS AND CONSIDERATIONS FOR THROMBOPHILIA TESTING--HOW CAN LABORATORIES SUPPORT PATIENTS? (PURPURA FULMINANS, ACUTE DIC, APAS, INTERFERENCES ETC. )
Donna Castellone.

7:00 - 8:00 PM

SATELLITE SYMPOSIUM

ASK THE EXPERTS: NAVIGATING GENE THERAPY FOR HEMOPHILIA - LIVED EXPERIENCE PERSPECTIVES FROM PATIENTS AND PROVIDERS (SPONSORED BY BIOMARIN)
Chicago Ballroom IX-X

Join us for dinner and hear from a panel of health care providers with hemophilia gene therapy experience (clinical trial and post-FDA approval), as well as patients with years of post-treatment experience. Panelists will review clinical trial data and discuss patient treatment outcomes and expectations. Have your questions answered by the panel and learn how gene therapy can be implemented in your Hemophilia Treatment Center.

ELEVATING HEMOPHILIA CARE BEYOND BLEED MANAGEMENT: A MULTIDISCIPLINARY PANEL DIALOGUE TO BRIDGE GAPS IN PATIENT CARE (SPONSORED BY SANOFI)
Chicago Ballroom VI

Please join us for our panel of healthcare providers and patients/caregivers for a discussion on current unmet needs in hemophilia centered around findings from a Hemophilia Life Stages and Changes Global Survey of >2, 700 patients, caregivers, and hematologists. As treatment options evolve, so must expectations and goals on management of hemophilia. This symposium will explore how communication gaps between HCPs and patients can improve to achieve positive change and better quality of life.